The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal haemorrhage admitted in intensive care

Submission date	Recruitment status	Prospectively registered
08/02/2007	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
08/02/2007	Completed	Results
Last Edited	Condition category	Individual participant data
04/03/2008	Circulatory System	[] Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr B M Kors

Contact details

VU University Medical Centre Afdeling intensive care volwassenen Boelelaan 1117 Amsterdam Netherlands 1081 HV + 31 (0)20 444 3900 bm.kors@vumc.nl

Additional identifiers

Protocol serial number N/A

Study information

Scientific Title

Study objectives

Describing the pharmacokinetics of nimodipine, especially the variability of the bio-availability of orally administred nimodipine.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Interventional, non-randomised, pharmacokinetic study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Subarachnoidal haemorrhage

Interventions

Blood samples according to strict time protocol during treatment.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Nimodipine

Primary outcome(s)

- 1. Pharmacokinetics of nimodipine in this specific group of patients
- 2. Variability of bio-availability of orally administred nimodipine

Key secondary outcome(s))

No secondary outcome measures

Completion date

01/12/2007

Eligibility

Key inclusion criteria

1. All patients admitted to the Intensive Care Unit (ICU) with subarachnoidal bleeding /haemorrhage (SAB), treated according to our SAB-protocol

2. Adults aged 18 to 70 years old

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Pregnancy
- 2. Expected mortality in less than 24 hours
- 3. Severe hepatic function disorders
- 4. Use of medication with known interaction in relation to nimodipine

Date of first enrolment

01/12/2006

Date of final enrolment

01/12/2007

Locations

Countries of recruitment

Netherlands

Study participating centre VU University Medical Centre

Amsterdam Netherlands 1081 HV

Sponsor information

Organisation

VU University Medical Centre (VUMC) (The Netherlands)

ROR

https://ror.org/00q6h8f30

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

VU University Medical Centre (VUMC) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration